JCR Pharmaceuticals Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4552.T | BIIB | NVS | AMGN | JNJ | GILD | |
|---|---|---|---|---|---|---|
| Market cap | 65.16B | 34.37B | 286.29B | 233.82B | 615.87B | 193.67B |
| P/E (TTM) | 79.7 | 41.3 | 22.8 | 26.9 | 38.8 | — |
| Forward P/E | 14.6 | 14.1 | 15.4 | 17.7 | 21.8 | 15.7 |
| Price/book | 1.5 | 1.8 | 6.9 | 20.0 | 7.2 | 16.4 |
| Dividend yield | 3.69% | — | 3.15% | 2.33% | 2.10% | 2.10% |
| 1-year change | −15.31% | +58.66% | +14.29% | +42.58% | +31.92% | +26.87% |
| Today | −1.48% | −1.15% | +0.16% | −0.35% | +0.90% | −0.75% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All 4552.T news ›JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- This approval follows the recent marketing authorization for IZCARGO™ in the United Arab Emirates - Kuwait is the second market outside Japan where IZCARGO™ has received approval, following the United Arab Emirates in July 2026. IZCARGO™…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
biospace.com2
-
en.ilsole24ore.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.